SecBot SecBot

GSK drug pipeline

GSK plc · 17 rated drugs
$50.41
−0.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.8%
1-day, median of 19 events
IV rank
No data
No current options data
Rated drugs
17
2 bullish · 1 bearish · 14 neutral
Phase 3 trials
12
4 with results posted

Upcoming catalysts

4 dated
  1. Dec 11, 2026
    MMB
    Phase 2 primary completion
  2. Jan 12, 2027
    Adjuvanted RSVPreF3 vaccine
    Phase 2 primary completion
  3. Jan 26, 2027
    Trelegy Ellipta
    Phase 3 primary completion
  4. Jan 2027
    Shingrix
    Phase 2 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled/PDUFA (NDA under FDA Priority Review)
Time to marketIf approved, US launch would follow the November 27, 2026 PDUFA date (~3 months away); approval is not guaranteed.

Neladalkib Updated Aug 18

What to watch

For GSK shareholders the near-term binary is November 27, 2026: FDA decision on neladalkib (with sibling ROS1 drug zidesamtinib's PDUFA on September 18, 2026 as a read-through). Note the direct equity upside of this drug was already captured, Nuvalent (NUVL) shareholders were cashed out at $124.00/share on July 15, 2026, so any remaining exposure is through mega-cap GSK, where one oncology NDA moves the stock by low single-digit percentages. Watch for FDA advisory-committee activity and any confirmatory-trial requirements before the PDUFA.

Bull case
  • FDA accepted the NDA with Priority Review and set a PDUFA target action date of November 27, 2026, a fast-tracked regulatory path for TKI pre-treated advanced ALK-positive NSCLC (local FDA-catalyst records, e.g. catalyst row dated 2026-08-05).
  • GSK paid $124.00/share in cash, a total equity value of approximately $10.6 billion and a ~40% premium to last close, for Nuvalent's lung-cancer assets, heavy conviction in neladalkib and its sibling zidesamtinib (GSK 6-K/8-K reports, June 2026).
  • Targets an unmet-need patient group, ALK-positive NSCLC that has already progressed on prior tyrosine kinase inhibitors, where resistance to older ALK drugs is a well-known problem (SEC catalyst records list the indication as TKI pre-treated advanced ALK-positive NSCLC).
Bear case
  • Approval is not assured: the November 27, 2026 PDUFA is a binary, and no confirmatory Phase 3 readout appears in the ingested trial data, the NDA is based on the earlier-stage program, leaving room for a CRL or additional-data requirements.
  • For GSK shareholders the impact is diluted: GSK is a ~$100B market-cap diversified pharma (per market snapshot in GSK 6-K, 2026-08-18), so one oncology NDA, win or lose, is a modest single-asset catalyst, not a make-or-break event.
  • GSK itself guided to low single-digit EPS dilution through FY2028 from the Nuvalent deal, with accretion only by 2029, the acquisition weighs on near-term earnings (GSK 6-K report, June 2026).
● neutral
Impact
PhaseApproved (Phase 3 / registrational Phase 2 for additional indications)
Time to marketAlready marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.

Jemperli dostarlimab Updated Jul 13

What to watch

Watch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.

Bull case
  • Only PD-1/PD-L1 inhibitor to show a statistically significant overall survival benefit in the frontline all-comer endometrial cancer setting, 31% reduction in risk of death vs chemo alone (RUBY Part 1 trial, 44.6 vs 28.2 months median OS).
  • AZUR-1 registrational data in dMMR/MSI-H rectal cancer (expected H2 2026) builds on an MSK-collaboration study showing 100% clinical complete response, potentially practice-changing if validated, opening a new indication with breakthrough therapy designation.
  • Commercial momentum is strong: Q3 2025 sales of $303M (+17% QoQ), YTD 2025 ~$785M; Q1 2026 oncology segment up 23% YoY (£512M). Consensus peak sales forecast ~$2.5B+ by 2030.
Bear case
  • Intense competition: Keytruda (Merck) and Imfinzi (AstraZeneca) are also approved in endometrial cancer, and Keytruda remains the dominant PD-1 franchise across multiple tumor types with vastly more commercial infrastructure.
  • Phase 3 FIRST/ENGOT-OV44 trial in ovarian cancer failed to show overall survival benefit for Jemperli + Zejula, mirroring Keytruda's failure in the same setting, suggesting PD-1 inhibition may not work in ovarian cancer.
  • Phase 3 ZEAL-1L trial in first-line NSCLC did not meet its primary PFS endpoint, curtailing a major market opportunity.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market (approved in US, EU, Japan, China, and other major markets)

Cabenuva cabotegravir and rilpivirine Updated Aug 24

What to watch

Cabenuva is an established, approved product with no imminent binary catalyst, watch GSK for overall pharma sector trends, HIV market share shifts vs. oral competitors and Gilead's Sunlenca, and ViiV's quarterly sales disclosures rather than a single drug event.

Bull case
  • First-to-market advantage: Cabenuva is the first and only FDA-approved complete long-acting injectable HIV regimen, offering a unique value proposition vs. daily oral pills, with 12 or 6 injection days per year.
  • Strong recent data: The LATITUDE Phase 3 trial (Feb 2026, NEJM) demonstrated Cabenuva's superiority over daily oral therapy in patients with adherence challenges, a large underserved segment that could expand the addressable market.
  • Adolescent expansion: Data from AIDS 2026 (July 2026) showed 94.4% viral suppression in adolescents with >97% preferring injections, supporting further label expansion into younger demographics.
Bear case
  • No upcoming binary catalyst: Cabenuva is already approved with no pending PDUFA or pivotal readout, limiting near-term stock-moving potential from this drug specifically.
  • Competitive pressure: Gilead Sciences' Sunlenca (lenacapavir) is a competing long-acting injectable HIV treatment. Daily oral generics remain a strong entrenched standard of care for most patients.
  • Commercial adoption headwinds: Long-acting injectables require in-office administration, patient visit compliance, and cold-chain logistics, which can slow uptake vs. convenient daily oral pills.
● neutral
Impact
PhasePhase 3
Time to marketPhase 3 trials started in August-September 2026 with estimated primary completion around July 2029 for the COPD studies and similar timelines for asthma and nasal polyps. If successful, a regulatory filing would likely follow in 2029-2030, with potential approval in the 2030-2031 timeframe.

felcorekibart Updated Oct 28

What to watch

Felcorekibart's Phase 3 PERSIST programme (six trials across COPD, asthma and nasal polyps) began enrollment in August-September 2026, with primary completion estimated around mid-2029. No top-line data, regulatory submission or PDUFA date is scheduled within the next 12 months, so the drug is not a near-term price catalyst for GSK. Investors should watch for any Phase 2 dose-finding data from the earlier asthma study (NCT05593250) as the next potential readout, but that trial's status is active/not recruiting with no posted results yet.

Bull case
  • Felcorekibart is designed as a long-acting anti-TSLP antibody with potential twice-yearly subcutaneous dosing, which could offer a significant convenience advantage over Tezspire (monthly dosing) if proven in trials.
  • The TSLP inhibitor market is growing rapidly: the global TSLP monoclonal antibody market was estimated at $1.94B in 2025 and projected to reach $7.8B by 2034 (14.4% CAGR). Tezspire's strong adoption validates the mechanism and leaves room for multiple entrants.
  • GSK has initiated an aggressive, broad Phase 3 PERSIST programme of six trials across three indications (COPD, uncontrolled asthma, and chronic rhinosinusitis with nasal polyps), expanding the drug's addressable market beyond severe asthma alone.
Bear case
  • Felcorekibart enters a crowded TSLP-targeting field already led by AstraZeneca/Amgen's Tezspire (tezepelumab), which generated ~$474M in Q4 2025 sales (~$1.9B annualised) and is growing 52-60% year-over-year. Other competitors such as Roche's lunsekimig (TSLPxIL-33 bispecific) and Windward Bio's WIN378 are also in development.
  • GSK's Phase 3 trials just began enrolling (August-September 2026); primary completion is estimated at mid-2029, meaning a potential approval would be years away with no near-term revenue contribution.
  • The drug originally came from Jiangsu Hengrui via Aiolos Bio, which GSK acquired for $1B upfront plus up to $400M in milestones. No Phase 2 efficacy data from a GSK-sponsored study has been publicly reported yet, so the drug's differentiation versus Tezspire remains unproven.
● neutral
Impact
PhasePhase 3
Time to marketUnknown; Phase 3 trials began enrolling in 2026. If successful, potential regulatory filings would be at least 2-4 years away (2028-2030).

mocertatug rezetecan Updated Oct 26

What to watch

GSK just presented updated BEHOLD-1 Phase 1b data at ESMO 2026 (Oct 23-27) showing a 62% confirmed ORR at the 5.8 mg/kg Phase 3 dose in platinum-resistant ovarian cancer. The next catalysts are Phase 3 interim/final readouts from the five pivotal trials (BEHOLD-Ovarian01, BEHOLD-Endometrial01, etc.) that began enrolling in 2026, those readouts are likely 2-3+ years away. For a large-cap pharma like GSK, this is one of many pipeline assets and not a near-term binary event.

Bull case
  • Phase 1b BEHOLD-1 data showed a 62% confirmed objective response rate at the selected Phase 3 dose (5.8 mg/kg) in platinum-resistant ovarian cancer, with median duration of response of 12.2 months and median PFS of 11.1 months, strong for a difficult-to-treat population.
  • GSK has rapidly advanced the asset into five global Phase 3 pivotal trials in 2026 (BEHOLD-Ovarian01, BEHOLD-Endometrial01, and others), signaling internal confidence.
  • B7-H4 is widely expressed in ovarian and endometrial cancers but low in normal tissues, offering a differentiated target; >95% of evaluable tumors in BEHOLD-1 were B7-H4-positive.
Bear case
  • Phase 3 trials have only begun enrolling in 2026; pivotal readouts are years away and could fail to replicate Phase 1 response rates.
  • Competition is intensifying: BeiGene's BG-C9074, another B7-H4-targeted ADC, has also entered Phase 3 for ovarian cancer, and Pfizer's PF-07260437 (B7-H4 bispecific) is in Phase 1.
  • GSK is a large-cap pharma (~$50B market cap) with dozens of marketed products; even a successful launch would be a modest contributor to overall revenue for years.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (COPD since 2017, asthma since 2020)

Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol Updated Aug 24

What to watch

Trelegy Ellipta is already approved and generating revenue, there is no near-term binary catalyst for GSK stock from this drug. Watch for Q1 2027 when a $100M milestone payment is expected from Theravance/Zymeworks, and monitor quarterly sales trends for signs of erosion from competitors like AstraZeneca's Breztri Aerosphere.

Bull case
  • Trelegy Ellipta was the first FDA-approved once-daily single-inhaler triple therapy for both COPD and asthma, giving it a durable first-mover advantage in a large and growing respiratory market.
  • The landmark Phase 3 IMPACT trial (52 weeks) showed Trelegy significantly reduced COPD exacerbations versus dual therapies (ICS/LABA and LAMA/LABA), supporting its clinical superiority narrative.
  • A $100 million Trelegy-related milestone payment is expected in Q1 2027 from the Theravance/Zymeworks transaction, providing a foreseeable catalyst.
Bear case
  • Patent expirations on components could eventually open the door to generic competition, pressuring pricing and market share.
  • AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is a direct triple-therapy competitor that could erode Trelegy's first-mover advantage.
  • As an already-approved, mature product, Trelegy offers no binary upside catalyst, GSK's stock moves will be driven by the broader pipeline and commercial execution, not this single drug.
● neutral
Impact
PhaseApproved (FDA, June 17, 2026)
Time to marketAlready approved (June 2026). US commercial launch expected by end of 2026.

Utebzi tebipenem pivoxil Updated Aug 24

What to watch

Utebzi is already approved and launching, no binary catalyst remains. For GSK investors, this is a small positive for the anti-infectives portfolio but not a needle-mover. For SPRO, the $105M royalty monetization (July 2026) has already reduced the stock's direct sensitivity to Utebzi sales; the next major SPRO catalysts will be around the SP001 immunology program (Phase 2 start expected Q2 2027), not Utebzi.

Bull case
  • First-in-class oral carbapenem addressing a clear unmet need for cUTI patients with resistant infections who lack oral alternatives, no direct oral competitor at launch.
  • Phase 3 PIVOT-PO trial showed non-inferiority to IV therapy, potentially reducing hospital stays and healthcare costs (targeting a $6B+ annual US healthcare cost market per Spero's estimates).
  • For SPRO, the $105M non-dilutive royalty monetization (July 2026) provided a cash runway into 2H 2029 with no further shareholder dilution tied to Utebzi.
Bear case
  • Already approved, the binary approval catalyst is past, leaving no near-term event to drive outsized stock returns for either GSK or SPRO.
  • For GSK, Utebzi is a very small contributor to a $106.5B market-cap pharma giant; consensus is 'Hold' (8 Buy, 6 Strong Buy, 15 Hold, 3 Sell) and near-term financial impact is modest.
  • For SPRO, analyst sentiment is bearish, 0 Buy, 3 Hold, 1 Sell, 2 Strong Sell, and the stock trades around $1.20, well below its 52-week high of $3.08.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (FDA approved December 2021)

Apretude cabotegravir Updated Aug 24

What to watch

Apretude is a commercial-stage asset with no near-term binary regulatory catalyst. Watch for quarterly ViiV sales disclosures within GSK's earnings, competitive threat from Gilead's evolving long-acting PrEP pipeline (e.g., lenacapavir), and any label-expansion updates. For GSK investors, Apretude is a growth contributor but not a standalone thesis driver.

Bull case
  • First and only long-acting injectable for HIV PrEP, a clear differentiation from daily oral pills (Truvada/Descovy), addressing adherence challenges
  • Real-world data showing >99% effectiveness and zero HIV acquisitions in implementation studies (CROI 2025) supports clinical and payer confidence
  • Approved in 50+ countries with positive NICE recommendation for NHS access in England and Wales (Oct 2025), expanding the addressable market
Bear case
  • Gilead's lenacapavir (Sunlenca), a twice-yearly injectable, is emerging as a potential competitive threat for PrEP, if approved, it would offer even less frequent dosing than Apretude's every-2-month schedule
  • As a branded specialty drug, Apretude faces payer access and reimbursement hurdles; generic oral PrEP options already exist at lower cost
  • GSK is a large, diversified pharma (consensus rating 'hold'), so Apretude's individual contribution is diluted across a massive pipeline, even material Apretude news is unlikely to move GSK stock significantly
● neutral
Impact
PhasePhase 2
Time to marketUncertain. Phase 2 is complete; GSK will need to design and execute Phase 3 trials before any regulatory filing, which typically takes 3-5+ years for a novel MASH therapy.

efimosfermin Updated Aug 24

What to watch

Monitor for GSK-initiated Phase 3 trial registration and for formal Phase 2 data disclosure at a hepatology conference (e.g., AASLD/EASL). Neither event has a confirmed date, so efimosfermin is not a near-term trading catalyst for GSK. The drug is a small pipeline component of a diversified pharma giant and carries limited stock-moving potential even on positive news.

Bull case
  • FDA Breakthrough Therapy and EMA PRIME designations signal strong Phase 2 efficacy and a clear regulatory path, these designations provide expedited review and more frequent FDA interaction, potentially accelerating development timelines.
  • MASH represents a massive unmet medical need with no approved therapies specifically indicated for advanced liver fibrosis due to MASH. Madrigal Pharmaceuticals' Rezdiffra (resmetirom) is the only FDA-approved MASH drug (for F2/F3 fibrosis), leaving enormous room for additional therapies.
  • GSK has deep pockets and a strong track record of advancing drugs through late-stage development, reducing the risk of financial constraints that often kill promising mid-stage assets at smaller biotechs.
Bear case
  • Efimosfermin is a tiny, early-stage asset within GSK's massive pipeline. GSK has a market capitalization of ~$106B, so even a successful MASH approval would have a modest effect on GSK's stock price on a percentage basis.
  • The MASH/NASH competitive landscape is crowded and littered with late-stage failures. Multiple large pharma drugs have failed Phase 2/3 trials, and Rezdiffra (Madrigal) already has first-mover advantage as the only approved therapy.
  • Phase 2 results have not been formally published or presented at a medical congress (hasResults=false on ClinicalTrials.gov as of the latest update), so investors cannot independently verify the efficacy signal that earned the breakthrough designations.
● neutral
Impact
PhaseApproved (FDA); supported by the ARROS-1 phase I/II pivotal trial
Time to marketApproved and on the market in the US (approval 2026-07-22); additional global/regulatory filings and a first-line label expansion pending

Jideytro zidesamtinib Updated Aug 21

What to watch

For GSK shareholders this is a strategic-validation story, not a share-price catalyst: the approval news is out, and GSK's three most recent FDA approvals (Lynavoy, Exdensur, Blenrep) were each followed by slightly negative one-day moves (avg -2.19%), consistent with a mega-cap where single drugs barely move the tape. Watch the planned 2H-2026 first-line sNDA submission and commercial uptake of Jideytro, plus sister asset neladalkib (ALK inhibitor) with its own PDUFA later in 2026, the bigger single-stock binary for the Nuvalent deal thesis.

Bull case
  • FDA approval on 2026-07-22 came roughly two months ahead of the original September 18, 2026 PDUFA date, a clean, accelerated regulatory win.
  • Approval validates GSK's ~$10.6B / $124-per-share cash acquisition of Nuvalent and marks GSK's first approved lung-cancer therapy; Nuvalent had ~$1.4B cash and runway into 2029, easing integration risk.
  • Designations support commercial positioning: orphan drug designation and breakthrough therapy designation for ROS1+ metastatic NSCLC previously treated with 2+ ROS1 TKIs (per FDA catalyst records).
Bear case
  • Niche market: ROS1-positive lung cancer is a small molecular subset (~50,000 annual diagnoses worldwide for the driver, per the company announcement), capping peak-sales potential.
  • Competition is real: the approved indication is for previously-treated disease, implying established ROS1-targeted therapies already exist, and Jideytro must win share in an increasingly crowded targeted-lung-cancer space.
  • The approval binary has passed, there is no pending PDUFA for Jideytro, and GSK's last three FDA approvals each saw negative 1-day stock reactions (Lynavoy -3.18%, Exdensur -1.08%, Blenrep -2.30%), showing single drugs barely move this mega-cap.
▲ bullish
Impact
PhasePhase 3
Time to market~3-4 years for global approval; China approval possible ~12-18 months post Hansoh filing

risvutatug rezetecan Updated Jul 10

What to watch

The ARTEMIS-008 Phase 3 win in China (positive OS vs topotecan in SCLC) is a major validation of the B7-H3 ADC mechanism, but for GSK investors the real catalyst is the global Phase 3 readout (primary completion now Oct 2027). Watch for China NDA filing timing and any early data from the ongoing EMBOLD/ARTEMIS expansion trials in prostate, NSCLC, and other solid tumors. With ~$1-2B peak sales potential (ex-China), risvutatug rezetecan is a meaningful but non-binary asset within GSK's broader pipeline.

Bull case
  • First positive Phase 3 OS data for any B7-H3 ADC globally, ARTEMIS-008 met its primary endpoint of overall survival vs topotecan in SCLC, a major mechanism validation (GSK press release, July 10, 2026).
  • Early Phase 1 ARTEMIS-001 data showed >60% ORR in extensive-stage SCLC and ~22% ORR in NSCLC, with 8.0 mg/kg dose selected for Phase 3 (Hansoh/AACR 2026 press release).
  • High peak sales potential: estimates peg ex-China peak at $1-2B assuming SCLC approval plus label expansion into B7-H3+ solid tumors (flcube.com, Dec 2025).
Bear case
  • Competition from ifinatamab deruxtecan (DS-7300, Daiichi Sankyo/Merck) is ahead, it already has FDA Breakthrough Therapy designation in pretreated ES-SCLC and is in Phase 3 (IDeate-Lung02) (Merck press release, Sep 2025).
  • China Phase 3 results (ARTEMIS-008) don't directly read across to global regulatory outcomes; GSK must run its own global Phase 3 (NCT07099898, primary completion pushed to Oct 2027) which adds ~2+ years to monetization.
  • As one of many pipeline assets at GSK ($44.8B revenue, ~$85B market cap), even a successful launch of this drug would have limited impact on GSK's overall share price.
● neutral
Impact
PhasePhase 3
Time to marketEstimated at least 5+ years away, given that both Phase 3 trials have primary completion dates around 2030-2032 and no regulatory submission has been announced.

velzatinib Updated Oct 28

What to watch

The next meaningful catalyst for velzatinib is continued enrollment and data updates from the two Phase 3 trials (StrateGIST Frontline and StrateGIST 3), but neither has a near-term readout given estimated primary completion dates around 2030-2032. Investors should watch for any interim analysis announcements or potential accelerated regulatory filing pathway discussions, though none are currently scheduled. For GSK, velzatinib is one of many pipeline assets and not a near-term binary driver for the stock.

Bull case
  • Velzatinib showed a 61% response rate in first-line GIST and 35-38% in second-line at ASCO 2026, with greater than 99% reductions in circulating tumor DNA across KIT mutations, suggesting broad and potent activity.
  • The drug is designed as a single-agent therapy targeting the full spectrum of primary and secondary KIT mutations, potentially offering a simpler treatment paradigm versus combination approaches like bezuclastinib plus sunitinib.
  • FDA has granted both Fast Track and Orphan Drug designations, which could accelerate development and provide market exclusivity upon approval.
Bear case
  • Both Phase 3 trials (StrateGIST Frontline and StrateGIST 3) have estimated durations of approximately 5 years, with primary completion dates around 2030-2032, meaning no near-term binary catalyst and a long wait for pivotal data.
  • Cogent Biosciences' bezuclastinib is a direct competitor that also presented compelling Phase 3 PEAK data at ASCO 2026, potentially capturing market share in second-line GIST before velzatinib can reach the market.
  • As a single asset within GSK's massive pipeline (166+ active trials), velzatinib's success or failure has limited impact on GSK's overall stock price, reducing its appeal as a catalyst-driven investment.
● neutral
Impact
PhaseApproved (FDA)
Time to marketAlready on the market (approved 2017)

Zejula niraparib Updated Aug 24

What to watch

Zejula is a mature, approved product within GSK's massive diversified portfolio, it is not a standalone binary catalyst. Investors should watch GSK's broader pipeline (vaccines, HIV, respiratory) and overall earnings rather than Zejula-specific news. The PARP inhibitor class faces increasing generic/biosimilar competition, so Zejula's revenue trajectory is likely to erode gradually rather than drive any single large stock move.

Bull case
  • Zejula remains a first-line maintenance option for ovarian cancer with a broad label covering all HRD-positive patients, supported by the PRIMA trial data.
  • GSK secured supplemental FDA approvals in 2025-2026 for labeling updates, keeping the product competitive.
  • Myriad Genetics received FDA approval for MyChoice CDx as the companion diagnostic for Zejula in March 2026, potentially expanding the addressable patient population by improving HRD testing access.
Bear case
  • Zejula faces intense competition from AstraZeneca/Merck's Lynparza (olaparib), which has a broader label and larger commercial footprint in the PARP inhibitor class.
  • Zai Lab reported declining Zejula sales in Greater China due to generic competition, signaling pricing pressure that may spread to other markets.
  • The PARP inhibitor class is maturing with multiple competitors, and Zejula has not demonstrated a clear efficacy or safety advantage over Lynparza.
● neutral
Impact
PhasePhase 1
Time to marketUnknown — early Phase 1; realistically several years from approval if it survives, and most Phase 1 oncology drugs do not reach the market.

NVL-330 Updated Aug 18

What to watch

For GSK (GSK) investors, NVL-330 is not a tradeable near-term catalyst, ignore it for the next year and instead track GSK's other acquired assets (neladalkib PDUFA Nov 27, 2026; zidesamtinib label expansion) and GSK's Q2-reaffirmed guidance. The only event to watch for NVL-330 specifically is early Phase 1 dose-escalation data at an oncology congress, for which no date was found in any source.

Bull case
  • Part of a strategic, already-closed $10.6B GSK acquisition (announced June 9, 2026; closed July 15, 2026 at $124.00/share cash) that builds a three-asset targeted-NSCLC franchise, the deal validation is done and GSK has the balance sheet to fund it (~$100B market cap).
  • HER2-mutant NSCLC is a defined genetic subset with a real need for selective oral HER2 inhibitors, and a HER2-selective TKI slots into an increasingly strong driver-focused lung-cancer portfolio alongside approved/under-review ROS1 and ALK drugs.
  • The same acquired portfolio has already delivered an FDA approval (Jideytro/zidesamtinib, approved July 2026 ahead of its PDUFA), suggesting GSK's integration and regulatory execution on these assets is working.
Bear case
  • Very early stage: NVL-330 is only Phase 1 with no clinical efficacy data in any source reviewed, typical Phase 1 attrition risk means a high probability it never becomes a commercial product.
  • Immaterial to GSK's stock near term: it is one small program inside a ~$100B company with no scheduled binary catalyst, so it cannot drive the share price by itself.
  • Deal drag: GSK guided to low single-digit EPS dilution from the Nuvalent deal through FY2028 and took a £1.9B impairment hit in Q2 2026 (largely the failed camlipixant trial), underscoring both the cost of the acquisition and GSK's overall pipeline-execution risk.
▼ bearish
Impact
PhasePhase 3 (lead indication discontinued); Phase IIb ongoing in IBS-D/IBS-M
Time to marketUnknown in the surviving IBS indication (Phase IIb — still years from any possible filing); effectively zero path to market in its lead indication, refractory chronic cough, where development was discontinued in July 2026.

camlipixant Updated Aug 19

What to watch

The defining binary has already passed and it was a miss: GSK booked a ~£1.9B impairment tied mostly to camlipixant that cut Q2 2026 operating profit by ~75% (to £481M), yet the stock is only a few percent off its 52-week high, confirming the drug is immaterial to a company this size. For GSK holders, watch the remaining Phase IIb IBS-D/IBS-M program for any signs of continued investment (or an eventual full exit from P2X3), and track competitors still chasing chronic cough (e.g., Trevi's Haduvio, Addex) as the class's commercial benchmark.

Bull case
  • CALM-1 did hit its primary endpoint (50mg BID at week 12), evidence of some genuine anti-cough signal at the higher dose, which is why GSK initially touted it.
  • Financial damage is contained: despite a ~£1.9B impairment, GSK reaffirmed 2026 guidance, and the ADR trades near its 52-week range (~$52.88 on Aug 19, 2026 vs $61.70 high), the market treats it as a one-off, not a franchise problem.
  • The molecule survives in a Phase IIb trial for IBS-D/IBS-M, a large indication where P2X3 blockade is mechanistically plausible, keeping a small optionality tail.
Bear case
  • The confirmatory Phase 3 CALM-2 trial FAILED to reach statistical significance on the primary endpoint at week 24, the exact result that decides whether a chronic-cough drug can be filed.
  • The 25mg dose missed in both CALM-1 and CALM-2, and key secondary endpoints did not meet thresholds, so there was no salvageable dose signal; GSK discontinued camlipixant in refractory chronic cough.
  • The failure directly hit the P&L: Q2 2026 total operating profit plunged ~75% to £481M on £1.9B of impairments 'primarily from the failed camlipixant trial'.

Fresh Drug Report

This drug report is still fresh. Subscribe to read its impact, phase, bull and bear case and thesis.

Subscribe for Full Access
● neutral
ImpactNot rated
PhaseNot stated
Time to marketNot stated

Dovato Updated Aug 24

What to watch

Dovato is a mature, approved product with no imminent FDA decision or pivotal readout, investors should watch quarterly ViiV/GSK HIV franchise sales for commercial momentum, and monitor competition from Gilead's Biktarvy and long-acting injectable therapies like Cabenuva (also ViiV). The next meaningful catalyst for GSK stock overall is more likely to come from a pipeline asset (e.g., depemokimab, blenrep data) than from Dovato specifically.

Other drugs in filings and trials

no drug report yet
  • LYNAVOY Last: Approval · Mar 17, 2026
  • EXDENSUR Last: Approval · Dec 16, 2025
  • BLENREP Last: Approval · Oct 23, 2025
  • BLUJEPA Last: Approval · Mar 25, 2025
  • OJJAARA Last: Approval · Sep 15, 2023
  • JESDUVROQ Last: Approval · Feb 1, 2023
  • BREXAFEMME Last: Approval · Jun 1, 2021
  • NUCALA Last: Approval · Jun 6, 2019
  • KRINTAFEL Last: Approval · Jul 20, 2018
  • BENLYSTA Last: Approval · Jul 20, 2017
  • ARNUITY ELLIPTA Last: Approval · Aug 20, 2014
  • TANZEUM Last: Approval · Apr 15, 2014
  • ANORO ELLIPTA Last: Approval · Dec 18, 2013
  • Adjuvanted RSVPreF3 vaccine 1 trial
  • Belantamab mafodotin 1 trial
  • Belimumab Injection 1 trial
  • Bepirovirsen 2 trials
  • Digoxin 1 trial
  • dTpa vaccine 1 trial
  • GSK1070806 2 trials
  • GSK3915393 1 trial
  • GSK4527226 1 trial
  • GSK4532990 2 trials
  • Mepolizumab 1 trial
  • MMB 1 trial
  • rMenB+OMV NZ vaccine 1 trial
  • Zanamivir 1 trial

Past FDA events & how the stock moved

19 events
DateDrugEvent1 day5 days
Mar 17, 2026LYNAVOYApproval−3.2%−1.5%
Dec 16, 2025EXDENSURApproval−1.1%−0.8%
Oct 23, 2025BLENREPApproval−2.3%+6.1%
Mar 25, 2025BLUJEPAApproval−0.7%−1.8%
Sep 15, 2023OJJAARAApproval−0.1%+0.1%
Apr 26, 2023ZejulaApproval−2.4%−0.2%
Feb 1, 2023JESDUVROQApproval−0.4%+3.0%
Aug 17, 2021JemperliApproval+0.2%−1.3%
Jun 1, 2021BREXAFEMMEApproval−1.0%+0.1%
Apr 22, 2021JemperliApproval−1.3%−2.0%
Jun 6, 2019NUCALAApproval+2.9%+3.8%
Jul 20, 2018KRINTAFELApproval+0.6%+0.2%
Sep 18, 2017Trelegy ElliptaApproval−0.8%+1.0%
Jul 20, 2017BENLYSTAApproval+0.6%−3.9%
Mar 27, 2017ZejulaApproval+0.2%−0.7%
Nov 4, 2015NUCALAApproval−0.5%−2.2%
Aug 20, 2014ARNUITY ELLIPTAApproval+0.7%+2.8%
Apr 15, 2014TANZEUMApproval+1.9%+6.4%
Dec 18, 2013ANORO ELLIPTAApproval+1.0%+2.6%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Trelegy ElliptaA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPhase 3Active not recruiting138Jan 26, 2027
Adjuvanted RSVPreF3 vaccineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney TransplantPhase 2Active not recruiting168Jan 12, 2027
ShingrixSafety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and AbovePhase 2Active not recruiting135Jan 2027
MMBExtended Access of Momelotinib in Adults With MyelofibrosisPhase 2Active not recruiting237Dec 11, 2026
JemperliA Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal CancerPhase 2Active not recruiting154Nov 2, 2026
dTpa vaccineA Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 YearsPhase 3Completed90Sep 4, 2026
JemperliA Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Phase 2Active not recruiting316Sep 1, 2026
DigoxinDigoxin Short Term Treatment Assessment Randomized Trial in AHFPhase 3Completed500Aug 31, 2026
Flu mRNA (Formulation B1)A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AbovePhase 2Completed971Aug 24, 2026
iNTS-GMMA Dose CA Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and InfantsPhase 2Completed180Aug 6, 2026
felcorekibartA Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled AsthmaPhase 2Active not recruiting307Jul 17, 2026
JemperliA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial CancerPhase 2Active not recruiting41Jul 15, 2026
JemperliEvaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)Phase 2Terminated2Jul 13, 2026
ZejulaA Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid TumorsPhase 2Active not recruiting42Jun 30, 2026
GSK4418959A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsPhase 2Active not recruiting14Jun 22, 2026
Belimumab InjectionSynergetic B-cell Immunomodulation in SLE - 2nd Study.Phase 3Completed71Jun 22, 2026
GSK4527226Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseasePhase 2Terminated367May 14, 2026
Flu mRNA (Formulation A)A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderPhase 2Completed776May 11, 2026
GSK4532990Phase 2b Study of GSK4532990 in Adults With NASHPhase 2Completed284Jan 31, 2026
ZanamivirAn Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza InfectionPhase 2Completed8Jan 14, 2026
Flu Pandemic mRNA_Dose level 1A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsPhase 2Completed991Jan 13, 2026
camlipixantA 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic CoughPhase 3Completed957Dec 17, 2025
rMenB+OMV NZ vaccineA Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)Phase 3Completed · results312Dec 15, 2025
BepirovirsenStudy of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)Phase 3Completed981Nov 11, 2025
BepirovirsenStudy of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)Phase 3Completed857Nov 3, 2025
MepolizumabStudy in Pediatrics With HypEREosinophilic Syndrome (SPHERE)Phase 3Completed · results16Oct 28, 2025
efimosferminA Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionPhase 2Completed231Oct 27, 2025
altSonflex1-2-3 Dose AA Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsPhase 2Completed · results200Oct 21, 2025
ZejulaA Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerPhase 2Completed117Oct 15, 2025
GSK3915393A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)Phase 2Terminated · results158Oct 1, 2025
GSK4532990Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASHPhase 2Completed · results61Sep 23, 2025
AFX3772A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy InfantsPhase 2Completed · results388Sep 18, 2025
ApretudeA Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyPhase 3Completed171Sep 16, 2025
GSK3511294 (Depemokimab)A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypePhase 3Completed · results1,717Sep 14, 2025
Salbutamol HFA-134aA Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaPhase 3Completed · results471Sep 2, 2025
GSK1070806Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.Phase 2Terminated · results79Jul 29, 2025
GSK1070806A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic DermatitisPhase 2Terminated · results161Jul 23, 2025
Belantamab mafodotinA Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisPhase 2Completed35Jul 17, 2025
AltSonflex1-2-3 High DoseA Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsPhase 2Completed · results551Jun 24, 2025
40 µg gE-gIA Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital HerpesPhase 2Completed · results504Jun 12, 2025